A rapid, selective, and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay has been proposed for the determination of aripiprazole in human plasma. The analyte and propranolol as internal standard (IS) were extracted from 200 μL of human plasma via liquid-liquid extraction using methyl tert-butyl ether under alkaline conditions. The best chromatographic separation was achieved on an Aquasil C18 (100 × 2.1 mm, 5 μm) column using methanol-deionized water containing 2 mM ammonium trifluoroacetate and 0.02% formic acid (65:35, v/v) as the mobile phase under isocratic conditions. Detection of analyte and IS was done by tandem mass spectrometry, operating in positive ion and multiple reaction monitoring (MRM) acquisition mode. The method was fully validated for its selectivity, interference check, sensitivity, carryover check, linearity, precision and accuracy, reinjection reproducibility, recovery, matrix effect, ion suppression/enhancement, stability, ruggedness, and dilution integrity. The assay was linear over the concentration range of 0.10–100 ng mL−1 for aripiprazole. The intra-batch and inter-batch precision (%CV) was ≤4.8%, while the mean extraction recovery was >96% for aripiprazole across quality control levels. The method was successfully applied to a bioequivalence study of 10 mg aripiprazole orally disintegrating tablet formulation in 27 healthy Indian subjects under fasting and fed condition. The reproducibility in the measurement of study data was demonstrated by reanalysis of 260 incurred samples.
[1]. E. Stip V. Tourjman 2010 Clin. Ther. 32 SupplA S3–S20.
[2]. R.S. McIntyre 2010 Clin. Ther. 32 SupplA S32–S38.
[3]. W.W. Fleischhacker R.D. McUuade R.N. Marcus D. Archibald R. Swanink W.H. Carson 2009 Biol. Psychiatry 65 510–517.
[4]. A. Deleon N.C. Patel M.L. Crismon 2004 Clin. Ther. 26 649–666.
[5]. Z.A. Sharif J.A. Lieberman 2009 Aripiprazole A.F. Schatzberg C.B. Nemeroff The American Psychiatric Publishing Textbook of Psychopharmacology 4th edn American Psychiatric Publications Inc. Washington DC 613–625.
[6]. M.D. Wood C. Scott K. Clarke J. Westaway C.H. Davies C. Reavill M. Hill C. Rourke M. Newson D.N.C. Jones I.T. Forbes A. Gribble 2006 Eur. J. Pharmacol. 546 88–94.
[7]. S.R. Marder R.D. McQuade E. Stock S. Kaplita R. Marcus A.Z. Safferman A.R. Saha M. Ali T. Iwamoto 2003 Schizophr. Res. 61 123–136.
[8]. S.G. Potkin A.R. Saha M.J. Kujawa W.H. Carson E. Stock J. Stringfellow G. Ingenito S.R. Marder 2003 Arch. Gen. Psychiatry 60 681–690.
[9]. ABILIFY (aripiprazole tablets) [prescribing information], New York, NY: Bristol-Myers Squibb Company, 2004; and Rockville, Md: Otsuka America Pharmaceutical, Inc., 2004. Available at http://www.abilify.com. Last assessed October 2011.
[10]. S. Mallikaarjun D.E. Salazaar S.L. Bramer 2004 J. Clin. Pharmacol. 44 179–187.
[11]. K.M. Kirschbaum J. Matthias M.J. Muller G. Zernig A. Saria A. Mobascher J. Malevani C. Hiemke 2005 Clin. Chem. 51 1718–1721.
[12]. Y. Shimokawa H. Akiyama E. Kashiyama T. Koga G.J. Miyanmoto 2005 J. Chromatogr. B 821 8–14.
[13]. X. Zuo F. Wang P. Xu R. Zhu H. Li 2006 Chromatographia 64 387–391.
[14]. A. Musenga M.A. Saracino D. Spinelli E. Rizzato G. Boncompagni E. Kenndler M.A. Raggi 2008 Anal. Chim. Acta 612 204–211.
[15]. S.N. Lin L. Lamm T.F. Newton M.S. Reid D.E. Moody R.L. Foltz 2009 J. Anal. Toxicol. 33 237–242.
[16]. F. Liang , A.V. Terry, and M.G. Bartlett, Biomed. Chromatogr. (2012), doi: 10.1002/bmc.2698.
[17]. M. Caloro L. Lionetto I. Cuomo A. Simonetti D. Pucci S.D. Persis B. Casolla G.D. Kotzalidis A. Sciarrette S.D. Filippis M. Simmaco P. Girardi 2012 J. Pharm. Biomed. Anal. 62 135–139.
[18]. M. Kubo Y. Mizooka Y. Hirao T. Osumi 2005 J. Chromatogr. B 822 294–299.
[19]. H.C. Huang C.H. Liu T.H. Lan T.M. Hu H.J. Chiu Y.C. Wu Y.L. Tseng 2007 J. Chromatogr. B 856 57–61.
[20]. F. Lancelin K. Djebrani K. Tabaouti L. Kraoul S. Brovedani P. Paubel M.L. Piketty 2008 J. Chromatogr. B 867 15–19.
[21]. M. Song X. Xu T. Hang A. Wen L. Yang 2009 Anal. Biochem. 385 270–277.
[22]. K.Y. Li Y.G. Zhou H.Y. Ren F. Wang B.K. Zhang H.D. Li 2007 J. Chromatogr. B 850 581–585.
[23]. C. Waldschmitt B. Pfuhlmann C. Hiemke 2009 Chromatographia 69 821–827.
[24]. E. Choong S. Rudaz A. Kottelat D. Guillarme J.L. Veuthey C.B. Eap 2009 J. Pharm. Biomed. Anal. 50 1000–1008.
[25]. H. Kirchherr W.N. Kühn-Velten 2006 J. Chromatogr. B 843 100–113.
[26]. Guidance for Industry, Bionanlytical Method Validation, US Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research (CDER), Centre for Veterinary Medicine (CVM), May 2001.
[27]. B.K. Matuszewski M.L. Constanzer C.M. Chavez-Eng 2003 Anal. Chem. 75 3019–3030.
[28]. R. King R. Bonfiglio C. Fernandez-Metzler C. Miller-Stein T. Olah 2000 J. Am. Soc. Mass Spectrom. 11 942–950.
[29]. Guidance for Industry: ICH E6 Good Clinical Practice, U.S. Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER), Centre for Biologics Evaluation and Research (CBER), 1996.
[30]. M. Yadav P.S. Shrivastav 2011 Bioanalysis 3 1007–1024.
[31]. M. Kubo T. Koue H. Maune T. Fukuda J. Azuma 2007 Drug Metab. Pharmacokinet. 22 358–366.
[32]. X.C. Zuo S.K. Liu Z.Y. Yi Z. Xie H.D. Li 2006 Curr. Ther. Res. 67 258–269.